Maxim raised the firm’s price target on Belite Bio (BLTE) to $200 from $140 and keeps a Buy rating on the shares after the company reported positive topline results from the Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE: